Bicycle Therapeutics(US:BCYC) Prnewswire·2025-12-11 15:00Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Bicycle Therapeutics plc regarding potential securities fraud or unlawful business practices [1] - RBC Capital Markets analyst downgraded Bicycle to Sector Perform from Outperform due to delays in the development of zelenectide pevedotin for metastatic urothelial cancer, which is now pushed to the first quarter of 2026 [2] - Following the downgrade, Bicycle's ADR price fell by $0.69, or 7.88%, closing at $8.07 on October 31, 2025 [3] Company Developments - The investigation by Pomerantz LLP focuses on whether Bicycle and its officers/directors have engaged in any fraudulent activities [1] - The delay in the development of zelenectide pevedotin is significant as the urothelial cancer treatment market is becoming increasingly competitive, with potential advantages for competing products, particularly from Pfizer [2] - The recent downgrade and subsequent price drop indicate investor concerns regarding Bicycle's market position and product development timeline [3]